• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一种用于肝细胞癌治疗的具有前景的缺氧敏感磁小体平台。

A promising platform of hypoxia sensitive magnetosomes in hepatocellular carcinoma therapy.

作者信息

Deng Kun, Wang Jiaojiao, Zhou Xia, Geng Yuanyuan, Liu Weiquan, Zhang Yiheng, Liu Yuangang, Jiang Wei

机构信息

State Key Laboratory of Animal Biotech Breeding, College of Biological Sciences, China Agricultural University, Beijing, 100193, China.

Institute of Pharmaceutical Engineering, Huaqiao University, Xiamen, 361021, China.

出版信息

Sci Rep. 2025 Jul 11;15(1):25031. doi: 10.1038/s41598-025-10353-y.

DOI:10.1038/s41598-025-10353-y
PMID:40646119
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12254477/
Abstract

Here, we engineered hypoxia-responsive nanoparticles (NI-HA-BMs-DOX) comprising 2-nitroimidazole (NI), hyaluronic acid (HA), bacterial magnetosomes (BMs), and doxorubicin (DOX) for targeted drug delivery. Under tumor hypoxia, the hypoxia-sensitive NI moiety undergoes reduction to 2-aminoimidazole, inducing a transition of the nanoparticles from a hydrophobic to a hydrophilic state, thereby facilitating controlled DOX release. Cellular assays demonstrated selective DOX delivery to HepG2 hepatocellular carcinoma cells under hypoxic conditions, while exhibiting minimal cytotoxicity toward normal hepatocytes (HL-7702). NI-HA-BMs-DOX significantly enhanced tumor cytotoxicity and apoptosis by upregulating caspase-3, caspase-8, and Tp53, demonstrating superior efficacy compared to free DOX and HA-BMs-DOX. In vivo studies further confirmed the therapeutic potential of NI-HA-BMs-DOX (4 mg/kg DOX equivalent), achieving a tumor inhibition rate of 55.38%, which exceeded that of HA-BMs-DOX (43.88%) and free DOX (34.90%). These findings validate NI-HA-BMs-DOX as a promising hypoxia-targeted therapeutic platform for HCC and highlight the potential of bacterial magnetosomes in improving drug delivery strategies for cancer treatment.

摘要

在此，我们设计了一种缺氧响应性纳米颗粒（NI-HA-BMs-DOX），其由2-硝基咪唑（NI）、透明质酸（HA）、细菌磁小体（BMs）和阿霉素（DOX）组成，用于靶向药物递送。在肿瘤缺氧条件下，对缺氧敏感的NI部分还原为2-氨基咪唑，诱导纳米颗粒从疏水状态转变为亲水状态，从而促进DOX的可控释放。细胞实验表明，在缺氧条件下，DOX可选择性递送至HepG2肝癌细胞，而对正常肝细胞（HL-7702）的细胞毒性极小。NI-HA-BMs-DOX通过上调caspase-3、caspase-8和Tp53显著增强了肿瘤细胞毒性和凋亡，与游离DOX和HA-BMs-DOX相比，显示出更高的疗效。体内研究进一步证实了NI-HA-BMs-DOX（4mg/kg DOX当量）的治疗潜力，其肿瘤抑制率达到55.38%，超过了HA-BMs-DOX（43.88%）和游离DOX（34.90%）。这些发现验证了NI-HA-BMs-DOX作为一种有前景的肝癌缺氧靶向治疗平台，并突出了细菌磁小体在改善癌症治疗药物递送策略方面的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/455eaab5f144/41598_2025_10353_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/2f0e06033f47/41598_2025_10353_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/a94b397ce76c/41598_2025_10353_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/b89d91fb1662/41598_2025_10353_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/def3f61d57ec/41598_2025_10353_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/925c0fa49071/41598_2025_10353_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/38e4c5e5228b/41598_2025_10353_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/23c6896baffa/41598_2025_10353_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/f1b8678ab87e/41598_2025_10353_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/2dcc023aa50b/41598_2025_10353_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/455eaab5f144/41598_2025_10353_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/2f0e06033f47/41598_2025_10353_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/a94b397ce76c/41598_2025_10353_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/b89d91fb1662/41598_2025_10353_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/def3f61d57ec/41598_2025_10353_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/925c0fa49071/41598_2025_10353_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/38e4c5e5228b/41598_2025_10353_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/23c6896baffa/41598_2025_10353_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/f1b8678ab87e/41598_2025_10353_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/2dcc023aa50b/41598_2025_10353_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/910c/12254477/455eaab5f144/41598_2025_10353_Fig10_HTML.jpg

相似文献

1
A promising platform of hypoxia sensitive magnetosomes in hepatocellular carcinoma therapy.一种用于肝细胞癌治疗的具有前景的缺氧敏感磁小体平台。
Sci Rep. 2025 Jul 11;15(1):25031. doi: 10.1038/s41598-025-10353-y.
2
Bacterial magnetosomes loaded with doxorubicin and transferrin improve targeted therapy of hepatocellular carcinoma.负载阿霉素和转铁蛋白的细菌磁小体改善肝细胞癌的靶向治疗。
Nanotheranostics. 2019 Jul 8;3(3):284-298. doi: 10.7150/ntno.34601. eCollection 2019.
3
Multi-Focused Acoustic Radiation Force Impulse Modulation of Murine Hepatic Xenografts Enhances Nanoscale DOX@Lip Delivery and Therapeutic Effect.小鼠肝异种移植瘤的多聚焦声辐射力脉冲调制增强纳米级阿霉素脂质体递送及治疗效果
Int J Nanomedicine. 2025 Jun 12;20:7359-7373. doi: 10.2147/IJN.S522247. eCollection 2025.
4
ROS-Responsive Nanosystem Targeted Co-Delivery YC-1 and Regorafenib to Alleviate Hypoxia Enhancing Hepatocellular Carcinoma Therapy.ROS响应性纳米系统靶向共递送YC-1和瑞戈非尼以减轻缺氧并增强肝细胞癌治疗效果
Int J Nanomedicine. 2025 Jul 1;20:8481-8496. doi: 10.2147/IJN.S518120. eCollection 2025.
5
Formononetin-induced apoptosis in hepatocellular carcinoma: insights from mTOR inhibition and caspase-3 activation through in silico and in vitro approaches.大豆苷元诱导肝癌细胞凋亡：通过计算机模拟和体外实验对mTOR抑制及半胱天冬酶-3激活的见解
Med Oncol. 2025 Jun 16;42(7):264. doi: 10.1007/s12032-025-02778-2.
6
Improving Chemotherapy Effectiveness: Utilizing CuS Nanoparticles Coated with AS1411 Aptamer and Chitosan for Targeted Delivery of Doxorubicin to Cancerous Cells.提高化疗效果：利用 AS1411 适体和壳聚糖包覆的 CuS 纳米粒子将阿霉素靶向递送至癌细胞。
J Pharm Sci. 2024 Jul;113(7):1865-1873. doi: 10.1016/j.xphs.2024.02.005. Epub 2024 Feb 10.
7
FOXM1 Aptamer-Polyethylenimine Nanoplatform Coated With Hyaluronic Acid And AS1411 Aptamer For Dual-Targeted Delivery of Doxorubicin And Synergistic Treatment of Tumor Cells.FOXM1 适体-聚乙烯亚胺纳米平台，经透明质酸和 AS1411 适体修饰，用于阿霉素的双重靶向递送和肿瘤细胞的协同治疗。
J Pharm Sci. 2024 Aug;113(8):2198-2207. doi: 10.1016/j.xphs.2024.02.025. Epub 2024 Mar 1.
8
Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.基于 Janus 纳米载体的阿霉素和小檗碱共递送减弱了化疗加剧的肝细胞癌复发。
Acta Biomater. 2019 Dec;100:352-364. doi: 10.1016/j.actbio.2019.09.034. Epub 2019 Sep 26.
9
Hyaluronic acid-modified extracellular vesicles for targeted doxorubicin delivery in hepatocellular carcinoma.透明质酸修饰的细胞外囊泡用于肝癌靶向多柔比星递送。
Exp Cell Res. 2024 Dec 1;443(2):114332. doi: 10.1016/j.yexcr.2024.114332. Epub 2024 Nov 16.
10
Glycyrrhetinic acid and RGD dual-targeted liposomes for combined chemotherapy and phototherapy in liver cancer.用于肝癌联合化疗和光疗的甘草次酸与RGD双靶点脂质体
Int J Pharm. 2025 Aug 20;681:125779. doi: 10.1016/j.ijpharm.2025.125779. Epub 2025 Jun 1.

本文引用的文献

1
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming.多柔比星和其他蒽环类药物在癌症中的应用：活性、化学耐药性及其克服。
Mol Aspects Med. 2023 Oct;93:101205. doi: 10.1016/j.mam.2023.101205. Epub 2023 Jul 27.
2
Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity.p53/BCL-2 复合物的结构提示了 p53 拮抗 BCL-2 活性的机制。
Nat Commun. 2023 Jul 18;14(1):4300. doi: 10.1038/s41467-023-40087-2.
3
Caspase-8 contributes to an immuno-hot microenvironment by promoting phagocytosis via an ecto-calreticulin-dependent mechanism.
半胱天冬酶-8通过一种依赖于胞外钙网蛋白的机制促进吞噬作用，从而有助于形成免疫激活的微环境。
Exp Hematol Oncol. 2023 Jan 12;12(1):7. doi: 10.1186/s40164-022-00371-1.
4
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape.缺氧诱导因子：缺氧肿瘤免疫逃逸的主调控因子。
J Hematol Oncol. 2022 Jun 3;15(1):77. doi: 10.1186/s13045-022-01292-6.
5
Topoisomerase II poisons inhibit vertebrate DNA replication through distinct mechanisms.拓扑异构酶 II 抑制剂通过不同的机制抑制脊椎动物 DNA 复制。
EMBO J. 2022 Jun 14;41(12):e110632. doi: 10.15252/embj.2022110632. Epub 2022 May 16.
6
Cellular mechanism of action of 2-nitroimidazoles as hypoxia-selective therapeutic agents.2-硝基咪唑类作为缺氧选择性治疗剂的细胞作用机制。
Redox Biol. 2022 Jun;52:102300. doi: 10.1016/j.redox.2022.102300. Epub 2022 Mar 21.
7
Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management.多柔比星诱导的心脏毒性：分子机制的最新研究进展及有效管理的新型治疗策略。
Biomed Pharmacother. 2021 Jul;139:111708. doi: 10.1016/j.biopha.2021.111708. Epub 2021 May 13.
8
Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives.癌症中靶向BCL-2：进展、挑战与展望
Cancers (Basel). 2021 Mar 14;13(6):1292. doi: 10.3390/cancers13061292.
9
Synthesis of Mitochondria-Anchored Nitroimidazoles with a Versatile NIR Fluorophore for Hypoxic Tumor-Targeting Imaging and Chemoradiotherapy.线粒体锚定的硝基咪唑类化合物的合成及其多功能近红外荧光探针用于缺氧肿瘤靶向成像和放化疗。
J Med Chem. 2021 Mar 25;64(6):3381-3391. doi: 10.1021/acs.jmedchem.0c02250. Epub 2021 Mar 10.
10
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc.去除癌症中的 Myc：直接抑制 c-Myc 的治疗策略。
Mol Cancer. 2021 Jan 4;20(1):3. doi: 10.1186/s12943-020-01291-6.